IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A method of treating at least one blood circulation disease in a patient in need thereof comprising administering at least one soluble HLA-G isoform to the patient in an amount sufficient to treat the at least one blood circulation disease The use of at least one soluble HLA-G isoform for preparing a medicinal product intended for use in the treatment of blood circulation diseases.

Claim 2 (Currently Amended): The use as claimed in The method of claim 1, characterized in that said diseases are wherein the at least one blood circulation disease is selected from the group consisting of anemias and ischemias.

Claim 3 (Currently Amended): A composition comprising at least one soluble HLA-G isoform and at least one pharmaceutically acceptable vehicle The use as claimed in claim 1 or claim 2, characterized in that said soluble HLA-G isoform is in the form of a composition also comprising at least one pharmaceutically acceptable vehicle.

Claim 4 (Currently Amended): The composition of Claim 3, wherein the composition is formulated as a liquid The use as claimed in claim 3, characterized in that said composition is in liquid form.

Claim 5 (Currently Amended): The composition of Claim 3, wherein the composition is formulated as a solid The use as claimed in claim 3, characterized in that said composition is in solid form.

Claim 6 (Currently Amended): A method of detecting and, optionally, sorting cells of the erythrocyte lines, ~~and~~ the endothelial ~~lines~~ lines, or combinations thereof, according to their state of differentiation, comprising ~~characterized in that it comprises:~~

a) bringing [[the]] a biological sample to be tested into contact with antibodies directed against the following markers: soluble HLA-G isoform, CD71, CD34 and CD45, and

b) detecting and, optionally, sorting cells corresponding to various stages of differentiation of the erythrocyte lines, [[or]] the endothelial lines, or a combination thereof ~~lines~~, according to their profile of expression of the markers defined in a).

Claim 7 (Currently Amended): The method as claimed in claim 6, ~~characterized in that it comprises:~~ further comprising

~~a) bringing the biological sample to be tested into contact with a panel of antibodies selected from the group consisting of antibodies directed against the following markers: soluble HLA-G isoform, CD71, CD34 and CD45, and~~

a') selecting the cells expressing the soluble HLA-G isoform, and

c) detecting the type of cell using the CD71 marker.

Claim 8 (Currently Amended): The method ~~of detection~~ of claim 6 ~~as claimed in claim 6 or claim 7~~, ~~characterized in that~~ wherein the biological sample is selected from the group consisting of a blood sample [[or]] and a bone marrow sample.

Claim 9 (Currently Amended): The method of <u>claim 6,</u> ~~detection as claimed in any one of claims 6 to 8, characterized in that,~~ <u>wherein</u> prior to ~~step~~ a), the cells of said biological sample are permeabilized.

Claim 10 (New): The method of claim 7, wherein the biological sample is selected from the group consisting of a blood sample and a bone marrow sample.

Claim 11 (New): The method of claim 7, wherein prior to a), the cells of said biological sample are permeabilized.

Claim 12 (New): The method of claim 8, wherein prior to a), the cells of said biological sample are permeabilized.